LYOS – INSERM U1033,
Team «Bone and Chronic Diseases»,
Université de Lyon, France.
Fragility fracture affects 45% of women after the menopause, and 20% of older men, with significant morbidity, increased mortality associated with of those fractures and substantial health care costs. Diagnostic and screening approaches rely on measurement of areal bone mineral density and the use of a few clinical risk factors. These approaches, however, lack sensitivity and specificity, so the development of new techniques, including non invasive measurement of bone microarchitecture, is warranted. Using three active cohorts (OFELY and QUALYOR in women, STRAMBO in men), we are testing the value of non invasive measurement of microarchitecture (with a peripheral microscanner and bone texture analysis) associated with biological markers.
We have a widely recognized expertise in bone histomorphometry and we have initiated or we participate to several clinical trials testing the value of drugs or strategies to manage the treatment of osteoporosis.
Bone is an organ with immune and endocrine functions. Bone metabolism is related to various conditions affecting other organs. Therefore, we study the influence of bone in several chronic diseases, including sarcopenia, osteoarthritis, rheumatic diseases and chronic kidney disease. To this end, we use well characterized cohorts (OFELY, QUALYOR, STRAMBO, IHODARI). We develop biological and imaging markers of the relationships between bone and extra-skeletal diseases. We participate to clinical trials in rheumatic diseases and osteoarthritis.
We are also exploring the epidemiology, natural history of fibrous dysplasia of bone (FRANCEDYS Cohort). We test new biomarkers and this diseases and we have conducted clinical trials to improve the treatment of this disease.